Zwitterionic near-infrared fluorophore for targeted photothermal cancer therapy. Issue 13 (4th March 2020)

• Record Type: Journal Article
• Authors: Lim, Wonbong; Jo, Gayoung; Kim, Eun Jeong; Cho, Hoonsung; Park, Min Ho; Hyun, Hoon
• Is Part Of: Journal of materials chemistry. Volume 8:Issue 13(2020)
• Page Start: 2589
• Page End: 2597
• Publication Date: 2020-03-04
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d0tb00275e
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : A zwitterionic NIR fluorophore ZW800-Cl showed intrinsic preferential tumor accumulation and an excellent photothermal capability without the need for chemical modifications with tumor-specific ligands and photosensitizers. Abstract : Precise photothermal cancer therapy still relies on the development of multifunctional theranostic agents to integrate tumor-specific targeting, imaging, and therapy. In this study, we identified the zwitterionic near-infrared (NIR) fluorophore ZW800-Cl, an analog of the well-known ZW800-1, and found that it preferentially accumulated in tumors in various xenograft models. We have demonstrated that the optical and physicochemical properties of ZW800-Cl are similar to those of ZW800-1, but it has a unique tumor targetability. Since ZW800-Cl showed binding selectivity to cancer cells in vitro, it could be specifically targeted to xenograft models of multiple tumor types, including MCF-7, NCI-H460, and HT-29. The in vivo results of photothermal cancer therapy indicated that the xenograft tumors could be effectively ablated by the combination of ZW800-Cl and an 808 nm laser irradiation. In this regard, our finding may provide a new approach for developing multifunctional cancer theranostic agents, setting them apart from conventional nanoparticles based on inorganic and polymeric materials. Therefore, ZW800-Cl may hold promise as a multifunctional theranostic agent for tumor-targeted imaging and effective photothermal cancer therapy.